Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents

被引：0

作者：

Marconi, Giovanni ^{[1
]}

Petracci, Elisabetta ^{[1
]}

Lanzarone, Giuseppe ^{[2
]}

Vetro, Calogero ^{[3
,4
]}

Martelli, Maria Paola ^{[5
]}

Papayannidis, Cristina ^{[6
]}

Audisio, Ernesta ^{[7
]}

Minetto, Paola ^{[8
]}

Riva, Carola ^{[8
]}

Guolo, Fabio ^{[8
]}

Martini, Gianluca ^{[9
]}

Zappasodi, Patrizia ^{[10
]}

Vincenzo, Federico ^{[11
]}

Gigli, Federica ^{[12
]}

Griguolo, Davide ^{[13
]}

Rondoni, Michela ^{[14
]}

Ciotti, Giulia ^{[15
]}

Borlenghi, Erika ^{[16
]}

Ciccone, Nadia ^{[17
]}

Palumbo, Fanny Erika ^{[3
]}

Nanni, Jacopo ^{[6
]}

Mattei, Daniele ^{[18
]}

Bernardi, Massimo ^{[19
]}

Cignetti, Alessandro ^{[20
]}

Zingaretti, Chiara ^{[1
]}

Vertogen, Bernadette ^{[1
]}

Cerchione, Claudio ^{[1
]}

Lanza, Francesco ^{[14
]}

Cilloni, Daniela ^{[21
]}

Brunetti, Lorenzo ^{[22
]}

Palmieri, Raffaele ^{[23
]}

Curti, Antonio ^{[6
]}

Giannini, Maria Benedetta ^{[1
]}

Todisco, Elisabetta ^{[24
]}

AVALON Res Grp, Nicola

Fracchiolla, Nicola ^{[25
]}

Martinelli, Giovanni ^{[1
,6
]}

机构：

[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Meldola, Italy

[2] AOU Citta Salute & Sci Torino, Ematol U, Turin, Italy

[3] AOU Policlin G Rodol San Marco, Div Ematol, Catania, Italy

[4] Azienda Sanit Alto Adige, UOC Ematol, Bolzano, Italy

[5] Univ Perugia, Osped Santa Maria Misericordia, Dipartimento Med & Chirurg, Perugia, Italy

[6] IRCCS Azienda Ospedaliero Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[7] AO Citta Salute & Sci, Complex Struct Hematol, Turin, Italy

[8] Univ Genoa, Dept Internal Med, Clin Hematol, Genoa, Italy

[9] Univ Pavia, Dept Mol Med, Pavia, Italy

[10] Fdn IRCCS Policlin San Matteo, Dipartimento Oncoematol, Pavia, Italy

[11] Osped Vito Fazzi, Unita Ematol & TCS, Lecce, Italy

[12] IRCCS Ist Europeo Oncol, Div Oncoematol, Milan, Italy

[13] ASU Giuliano Isontina, SC Ematol, Trieste, Italy

[14] AUSL Romagna, Osped S Maria Croci, UO Ematol, Ravenna, Italy

[15] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Onco Hematol, Padua, Italy

[16] Spedali Civili, Hematol, Brescia, KY USA

[17] Azienda Ospedaliero Univ Ferrara, SC Ematol, Ferrara, Italy

[18] ASO S Croce & Carle, Complex Struct Hematol, Cuneo, Italy

[19] IRCCS Osped San Raffaele, UO Ematol & Ctr Trapianto Midollo Osseo, Milan, Italy

[20] AO Ordine Mauriziano, SCDU Ematol & Terapie Cellulari, Turin, Italy

[21] Univ Turin, Dept Clin & Biol Sci, Orbassano, Italy

[22] Univ Politecn Marche, Dept Clin & Mol Sci, Ancona, Italy

[23] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy

[24] ASST Valle Olona, Osped Busto Arsizio, SC Ematol, Varese, Italy

[25] Fdn IRCCS CaGranda Osped Maggiore Policlin, UOC Oncoematol, Milan, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 04期

关键词：

acute myeloid leukemia; AML; fitness; low intensity therapy;

D O I：

10.1002/ajh.27591

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：708 / 711

页数：4

共 50 条

[1] The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study
Marconi, Giovanni
Candoni, Anna
Di Nicola, Roberta
Sartor, Chiara
Parisi, Sarah
Abbenante, Mariachiara
Nanni, Jacopo
Cristiano, Gianluca
Zannoni, Letizia
Lazzarotto, Davide
Giannini, Benedetta
Baldazzi, Carmen
Bandini, Lorenza
Ottaviani, Emanuela
Testoni, Nicoletta
Bezzi, Chiara Di Giovanni
Abd-alatif, Rania
Ciotti, Giulia
Fanin, Renato
Martinelli, Giovanni
Paolini, Stefania
Ricci, Paolo
Cavo, Michele
Papayannidis, Cristina
Curti, Antonio
CANCER MEDICINE, 2023, 12 (10): : 11838 - 11848
[2] A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Shahswar, Rabia
Gabdoulline, Razif
Krueger, Katja
Wichmann, Martin
Goetze, Katharina S.
Braitsch, Krischan
Meggendorfer, Manja
Schmalbrock, Laura
Bullinger, Lars
Modemann, Franziska
Fiedler, Walter
Krauter, Juergen
Kaun, Stephan
Rotermund, Susanne
Voss, Andreas
Behrens, Yvonne Lisa
Bergmann, Anke Katharina
Koller, Elisabeth
Beutel, Gernot
Thol, Felicitas
Heidel, Florian
Heuser, Michael
LEUKEMIA, 2025, 39 (03) : 614 - 622
[3] Results of Treatment With Hypomethylating Agents Versus Hypomethylating Agents/Venetoclax in Patients With AML Single-Center Experience
Patino, Ana Flavia
Brulc, Erika
Conca, Alberto Gimenez
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S289 - S289
[4] Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents
Papayannidis, Cristina
Nanni, Jacopo
Cristiano, Gianluca
Marconi, Giovanni
Sartor, Chiara
Parisi, Sarah
Zannoni, Letizia
Saed, Rashed
Ottaviani, Emanuela
Bandini, Lorenza
Testoni, Nicoletta
Baldazzi, Carmen
Solli, Vincenza
Ricci, Paolo
Di Giovanni Bezzi, Chiara
Abd-alatif, Rania
Stanzani, Marta
Paolini, Stefania
Cavo, Michele
Curti, Antonio
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (06) : 449 - 459
[5] Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax
Shimony, Shai
Garcia, Jacqueline S.
Keating, Julia
Chen, Evan C.
Luskin, Marlise R.
Stahl, Maximilian
Neuberg, Donna S.
DeAngelo, Daniel J.
Stone, Richard M.
Lindsley, Coleman
BLOOD, 2023, 142
[6] Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
Jin, Dian
He, Jingsong
Chen, Haoguang
Wu, Wenjun
Han, Xiaoyan
Le, Jing
Shu, Wenxiu
Yang, Qianqian
Pei, Shanshan
Cai, Zhen
He, Donghua
CANCER MEDICINE, 2024, 13 (14):
[7] Elevated pre-treatment fetal hemoglobin is a predictor of better outcome in MDS/AML patients receiving DNA-hypomethylating treatment
Stomper, J.
Ihorst, G.
Sander, P. N.
Bogatyreva, L.
Becker, H.
Wijermans, P. W.
Suciu, S.
Bisse, E.
Claus, R.
Luebbert, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 180 - 180
[8] Clinical outcomes of patients receiving venetoclax and hypomethylating agents for AML in academic and academic-community partnerships
Pham, Natalie
Lantz, Jeffrey
Jones, Caroline
Kundu, Debamita
McCann, Nicholas
El Chaer, Firas
Reed, Daniel
Keng, Michael Kenneth
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
Zainaldin, Carl
Arora, Sankalp
Bathini, Srilakshmi
Gupta, Udita
Pandya, Vishruti
Bae, Sejong
Worth, Sarah
Bachiashvili, Kimo
Bhatia, Ravi
Godby, Kelly
Jamy, Omer
Rangaraju, Sravanti
Diamond, Barry
Oliver, Josh D.
Salzman, Donna
Di Stasi, Antonio
Vachhani, Pankit
LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3245 - 3248
[10] Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax plus hypomethylating agents
Johnson, Isla M.
Karrar, Omer
Rana, Masooma
Iftikhar, Moazah
Chen, Sunny
McCullough, Kristen
Saliba, Antoine N.
Al-Kali, Aref
Alkhateeb, Hassan
Begna, Kebede
Litzow, Mark
Hogan, William J.
Shah, Mithun
Patnaik, Mrinal M.
Pardanani, Animesh
Hermann, Joerg
Tefferi, Ayalew
Gangat, Naseema
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1232 - 1237

← 1 2 3 4 5 →